68 related articles for article (PubMed ID: 24070783)
1. Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl)ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic pain.
Wu YJ; Conway CM; Sun LQ; Machet F; Chen J; Chen P; He H; Bourin C; Calandra V; Polino JL; Davis CD; Heman K; Gribkoff VK; Boissard CG; Knox RJ; Thompson MW; Fitzpatrick W; Weaver D; Harden DG; Natale J; Dworetzky SI; Starrett JE
Bioorg Med Chem Lett; 2013 Nov; 23(22):6188-91. PubMed ID: 24070783
[TBL] [Abstract][Full Text] [Related]
2. (S,E)-N-[1-(3-heteroarylphenyl)ethyl]-3-(2-fluorophenyl)acrylamides: synthesis and KCNQ2 potassium channel opener activity.
L'Heureux A; Martel A; He H; Chen J; Sun LQ; Starrett JE; Natale J; Dworetzky SI; Knox RJ; Harden DG; Weaver D; Thompson MW; Wu YJ
Bioorg Med Chem Lett; 2005 Jan; 15(2):363-6. PubMed ID: 15603955
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and KCNQ2 opener activity of N-(1-benzo[1,3]dioxol-5-yl-ethyl, N-[1-(2,3-dihydro-benzofuran-5-yl)-ethyl, and N-[1-(2,3-dihydro-1H-indol-5-yl)-ethyl acrylamides.
Wu YJ; Sun LQ; He H; Chen J; Starrett JE; Dextraze P; Daris JP; Boissard CG; Pieschl RL; Gribkoff VK; Natale J; Knox RJ; Harden DG; Thompson MW; Fitzpatrick W; Weaver D; Wu D; Gao Q; Dworetzky SI
Bioorg Med Chem Lett; 2004 Sep; 14(17):4533-7. PubMed ID: 15357987
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationship of acrylamides as KCNQ2 potassium channel openers.
Wu YJ; He H; Sun LQ; L'Heureux A; Chen J; Dextraze P; Starrett JE; Boissard CG; Gribkoff VK; Natale J; Dworetzky SI
J Med Chem; 2004 May; 47(11):2887-96. PubMed ID: 15139767
[TBL] [Abstract][Full Text] [Related]
5. (S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons.
Wu YJ; Boissard CG; Chen J; Fitzpatrick W; Gao Q; Gribkoff VK; Harden DG; He H; Knox RJ; Natale J; Pieschl RL; Starrett JE; Sun LQ; Thompson M; Weaver D; Wu D; Dworetzky SI
Bioorg Med Chem Lett; 2004 Apr; 14(8):1991-5. PubMed ID: 15050644
[TBL] [Abstract][Full Text] [Related]
6. The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels.
Bentzen BH; Schmitt N; Calloe K; Dalby Brown W; Grunnet M; Olesen SP
Neuropharmacology; 2006 Nov; 51(6):1068-77. PubMed ID: 16904708
[TBL] [Abstract][Full Text] [Related]
7. (S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine.
Wu YJ; Boissard CG; Greco C; Gribkoff VK; Harden DG; He H; L'Heureux A; Kang SH; Kinney GG; Knox RJ; Natale J; Newton AE; Lehtinen-Oboma S; Sinz MW; Sivarao DV; Starrett JE; Sun LQ; Tertyshnikova S; Thompson MW; Weaver D; Wong HS; Zhang L; Dworetzky SI
J Med Chem; 2003 Jul; 46(15):3197-200. PubMed ID: 12852750
[TBL] [Abstract][Full Text] [Related]
8. In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models.
Roeloffs R; Wickenden AD; Crean C; Werness S; McNaughton-Smith G; Stables J; McNamara JO; Ghodadra N; Rigdon GC
J Pharmacol Exp Ther; 2008 Sep; 326(3):818-28. PubMed ID: 18577704
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional repression of the M channel subunit Kv7.2 in chronic nerve injury.
Rose K; Ooi L; Dalle C; Robertson B; Wood IC; Gamper N
Pain; 2011 Apr; 152(4):742-754. PubMed ID: 21345591
[TBL] [Abstract][Full Text] [Related]
10. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.
Wickenden AD; Krajewski JL; London B; Wagoner PK; Wilson WA; Clark S; Roeloffs R; McNaughton-Smith G; Rigdon GC
Mol Pharmacol; 2008 Mar; 73(3):977-86. PubMed ID: 18089837
[TBL] [Abstract][Full Text] [Related]
11. Activation of Neuronal Voltage-Gated Potassium Kv7/KCNQ/M-Current by a Novel Channel Opener SCR2682 for Alleviation of Chronic Pain.
Wang J; Liu Y; Hu F; Yang J; Guo X; Hou X; Ju C; Wang K
J Pharmacol Exp Ther; 2021 Apr; 377(1):20-28. PubMed ID: 33431609
[TBL] [Abstract][Full Text] [Related]
12. Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.
Wu YJ; Davis CD; Dworetzky S; Fitzpatrick WC; Harden D; He H; Knox RJ; Newton AE; Philip T; Polson C; Sivarao DV; Sun LQ; Tertyshnikova S; Weaver D; Yeola S; Zoeckler M; Sinz MW
J Med Chem; 2003 Aug; 46(18):3778-81. PubMed ID: 12930139
[TBL] [Abstract][Full Text] [Related]
13. The K(V)7.2/3 preferring channel opener ICA 27243 attenuates L-DOPA-induced dyskinesia in hemiparkinsonian rats.
Sander SE; Lambrecht C; Richter A
Neurosci Lett; 2013 Jun; 545():59-63. PubMed ID: 23623937
[TBL] [Abstract][Full Text] [Related]
14. KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.
Zhang D; Thimmapaya R; Zhang XF; Anderson DJ; Baranowski JL; Scanio M; Perez-Medrano A; Peddi S; Wang Z; Patel JR; DeGoey DA; Gopalakrishnan M; Honore P; Yao BB; Surowy CS
J Neurosci Methods; 2011 Aug; 200(1):54-62. PubMed ID: 21723881
[TBL] [Abstract][Full Text] [Related]
15. RNA interference-mediated silencing of Kv7.2 in rat dorsal root ganglion neurons abolishes the anti-nociceptive effect of a selective channel opener.
Valdor M; Wagner A; Fischer H; Röhrs V; Schröder W; Bahrenberg G; Welbers A; Fechner H; Kurreck J; Tzschentke TM; Christoph T
J Pharmacol Toxicol Methods; 2020; 103():106693. PubMed ID: 32276047
[TBL] [Abstract][Full Text] [Related]
16. RNA interference-based functional knockdown of the voltage-gated potassium channel Kv7.2 in dorsal root ganglion neurons after in vitro and in vivo gene transfer by adeno-associated virus vectors.
Valdor M; Wagner A; Röhrs V; Berg J; Fechner H; Schröder W; Tzschentke TM; Bahrenberg G; Christoph T; Kurreck J
Mol Pain; 2018; 14():1744806917749669. PubMed ID: 29212407
[TBL] [Abstract][Full Text] [Related]
17. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
Padilla K; Wickenden AD; Gerlach AC; McCormack K
Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
[TBL] [Abstract][Full Text] [Related]
18. Activation of KCNQ2/3 potassium channels by novel pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives.
Jia C; Qi J; Zhang F; Mi Y; Zhang X; Chen X; Liu L; Du X; Zhang H
Pharmacology; 2011; 87(5-6):297-310. PubMed ID: 21577044
[TBL] [Abstract][Full Text] [Related]
19. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.
Peretz A; Degani N; Nachman R; Uziyel Y; Gibor G; Shabat D; Attali B
Mol Pharmacol; 2005 Apr; 67(4):1053-66. PubMed ID: 15598972
[TBL] [Abstract][Full Text] [Related]
20. Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels.
Punke MA; Friederich P
Anesth Analg; 2007 May; 104(5):1256-64, tables of contents. PubMed ID: 17456683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
